- Home
- VOR vs TNYA Comparison
VOR vs TNYA Comparison
Compare VOR & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOR | TNYA |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | 97 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 234.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VOR | TNYA |
|---|---|---|
| Price | $8.13 | $1.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $70.43 | $8.60 |
| AVG Volume (30 Days) | 1.1M | ★ 2.4M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.62 | $0.36 |
| 52 Week High | $65.80 | $4.01 |
Technical Indicators
Market Signals| Indicator | VOR | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 29.79 | 52.56 |
| Support Level | $7.21 | $1.21 |
| Resistance Level | $8.60 | $1.42 |
| Average True Range (ATR) | 0.87 | 0.10 |
| MACD | 0.55 | 0.02 |
| Stochastic Oscillator | 44.80 | 96.36 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.